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Therapeutic Strategies for Systemic
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ABSTRACT
Treatments of vasculitides have progressed markedly over the past few decades. The first attempts to obtain
better-adapted therapeutic strategies evaluated the indications of conventional drugs, and their abilities prolong
survival and reduce the number of relapses, while decreasing the severity and number of side effects. Many
prospective clinical trials were organized by the French Vasculitis Study Group and the European Vasculitis
Study group, and have contributed to optimizing targeted treatment strategies. Recent therapeutic strategies in-
clude immunomodulating methods, like plasma exchanges, or products, like intravenous immunoglobulins, or,
more recently, new agents called biotherapies. Some of them have achieved promising positive effects, for ex-
ample, anti-CD20 monoclonal antibodies, and are now being evaluated in prospective trials.
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INTRODUCTION
Over the past few decades, treatment of systemic ne-
crotizing vasculitides (SNV) has become more effec-
tive and the outcomes of all these vasculitides im-
proved. Several advances explain this improvement:
better knowledge of the classification of these dis-
eases, treatments adapted to their respective etiolo-
gies and pathogeneses when they could be deter-
mined, progress in the care of severe and life-
threatening manifestations, treatment adapted to pa-
tient’s condition and age. Herein, we review the dif-
ferent therapeutic strategies that are currently ap-
plied to patients and report on the new drugs that are
currently being evaluated for SNV treatment.
CLASSIFICATION
Inflammation and necrosis of blood-vessel walls are
characteristic of SNV. All sizes of blood vessels―
from the aorta to capillaries―can be affected by the
vasculitic process. Different vasculitides have been
identified and several classification systems have
been proposed. The American College of Rheumatol-
ogy defined different classification criteria for vasculi-
tides1-3 but the classification that has been unani-
mously adopted by the scientific community to differ-
entiate polyarteritis nodosa (PAN) from microscopic
polyangiitis (MPA), is the Chapel Hill Nomenclature
(Table 1).4 This nomenclature defines, among small-
sized-vessel vasculitides a group of diseases charac-
terized by the presence of antineutrophil cytoplasm
antibodies (ANCA): Wegener’s granulomatosis
(WG), MPA, Churg-Strauss syndrome (CSS) and
renal-limited vasculitis. The frequency of ANCA posi-
tivity differs from one vasculitis to another: ANCA are
present in more than 80% of WG patients,5 around
75% of MPA6 but only 40% of those with CSS.7,8
PREDICTIBLE OUTCOME
The outcomes of SNV also differ from one entity to
another and their respective relapse rates also vary,
from less than 10% for hepatitis B virus-related PAN
(HBV-PAN)9 to 23.4% for CSS,10 34.1% for MPA6 and
more than 50% for WG.11 Treatment duration should
probably be decided, at least in part, according to the
risk of relapse. Shorter-term treatments might be
suitable for mild forms of PAN. For WG, prolonged
therapy does not seem able to lower the relapse rate
below 50%,11 although treatments given for less than
1 year are almost always associated with a high re-
lapse rate, ranging from 50 to 100%.
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Table 1 Names and definitions adopted by the Chapel Hil Consensus Conference on the nomenclature of systemic vasculiti-
des ＊ .
Large-vessel vasculitides
Granulomatous arteritis of the aorta and its major branches, with a predilection for 
the extracranial branches of the carotid artery. Often involves the temporal artery. 
Usualy occurs in patients over 50 years old and often is associated with polymy-
algia rheumatica.
Giant cel (temporal) arteritis
Granulomatous arteritis of the aorta and its major branches.
Usualy occurs in patients younger than 50.
Takayasu’ sarteritis
Medium-sized vessel vasculitides
Necrotizing inflammation of medium-sized or smal arteries without glomerulonephri-
tis or vasculitis in arterioles, capilaries, or venules.
Polyarteritis nodosa
 (classic polyarteritis nodosa)
Arteritis involving large, medium-sized, and smal arteries, and associated with muco-
cutaneous lymph-node syndrome.
Coronary arteries are often involved. Aorta and veins can be involved. Usualy oc-
curs in children. 
Kawasaki disease
Smal-vessel vasculitides
Granulomatous inflammation involving the respiratory tract and necrotizing vasculitis 
afecting smal- to medium-sized vessels (e.g., capilaries, venules, arterioles 
and/or arteries).
Necrotizing glomerulonephritis is common.
Wegener’ sgranulomatosis＊＊
Eosinophil-rich and granulomatous inflammation involving the respiratory tract, and 
necrotizing vasculitis afecting smal- to medium-sized vessels, associated with 
asthma and eosinophilia.
Churg-Strauss syndrome＊＊
Necrotizing vasculitis, with few or no immune deposits, afecting smal vessels (i.e., 
capilaries, venules and/or arterioles). 
Necrotizing arteritis involving smal- and medium-sized vessels can be present. 
Necrotizing glomerulonephritis is very common. Pulmonary capilaritis often 
occurs.
Microscopic polyangitis＊＊
(microscopic polyarteritis)
Vasculitis, with IgA-dominant immune deposits, afecting smal vessels (i.e., capilar-
ies, venules and/or arterioles).
Typicaly involves skin, gut, and glomeruli, and is associated with arthralgias or 
arthritis.
Henoch-Schönlein purpura
Vasculitis, with cryoglobulin immune deposits, afecting smal vessels (i.e., capilari-
es, venules and/or arterioles), and associated with cryoglobulins in serum.
Skin and glomeruli are often involved.
Cryoglobulin-associated vasculitis
Isolated cutaneous leukocytoclastic angitis without systemic vasculitis or 
glomerulonephritis.
Cutaneous leukocytoclastic angitis
＊Adapted from4. Large vessels refers to the aorta and its largest branches directed toward major body regions (e.g. to the extremities 
and the head and neck); medium-sized vessels refers to the main visceral arteries (e.g. renal, hepatic, coronary and mesenteric arteries); 
smal vessels refers to venules, capilaries, arterioles and the intraparenchymal distal arteries that connect with arterioles. Some smal- 
and large-vessel vasculitides can involve medium-sized arteries, but large- and medium-sized―vessel vasculitides do not involve ves-
sels smaler than arteries. Essential components are represented by normal type; italics represent usual, but not essential, components. 
＊＊Strongly associated with antineutrophil cytoplasm autoantibodies.
ETIOLOGIES
The etiologies of a few SNV cases have been identi-
fied, with viral or bacterial infections proven or con-
sidered likely. HBV is recognized as the etiological
agent of a minority of patients with systemic vasculiti-
des (less than 1%) but it could be of major importance
in PAN for which it has been incriminated as being
responsible for more than one-third of the cases.9 Hu-
man immunodeficiency virus (HIV),12 parvovirus B19
and Epstein-Barr virus have been observed in rare
cases and thus should be actively sought. Hepatitis C
virus (HCV) is now considered to be the etiological
agent of mixed cryoglobulin-associated vasculitis in
more than 90% of the patients.13
TREATMENT OF HBV- AND OTHER VIRUS-
RELATED PAN
HBV-PAN
In the context of chronic hepatitis B, corticosteroids
and immunosuppressive agents, despite having
proven efficacy against the vasculitis symptoms, also
have deleterious effects: they enhance virus replica-
tion, and, over the long term, they perpetuate chronic
HBV infection and facilitate progression towards cir-
rhosis, which may be complicated later by hepatocel-
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lular carcinomas.
Based on the efficacy of antiviral agents against
chronic hepatitis and of plasma exchanges (PE) for
PAN, we combined the two therapies to treat HBV-
PAN. The rationale of the therapeutic sequence was
as follows: initial corticosteroids to rapidly control the
most severe life-threatening PAN manifestations,
which are common during the first weeks of the dis-
ease, and their abrupt stoppage to enhance immu-
nological clearance of HBV-infected hepatocytes and
favor HBe antigen (Ag) to anti-HBe antibody (Ab) se-
roconversion; with PE to control the course of PAN.
In HBV-PAN, the combination of an antiviral agent
(vidarabine, interferon-alpha 2b (IFNα2b) or, more
recently, lamivudine) and PE gave excellent overall
therapeutic results, and should be preferred to the
more dangerous (in this setting) conventional regi-
mens.9 However, that strategy does not improve
short-term survival compared to corticosteroids and
cyclophosphamide (CYC), but increases the HBeAg-
to-HBeAb seroconversion rate from 14.7% with con-
ventional treatment to 49.4% when patients were
treated with an antiviral agent and PE.9
HCV-RELATED CRYOGLOBULIN-ASSOCIATED
VASCULITIS
This vasculitis is asymptomatic in the majority of pa-
tients but persists for decades and its duration could
be a factor associated with the occurrence of clinical
symptoms. No treatment is able to cure all cases of
mixed cryoglobulin-associated vasculitis and an opti-
mal therapeutic strategy has not yet been clearly de-
fined. In asymptomatic patients, close monitoring
could suffice but early treatment can also be consid-
ered. For patients with moderate symptoms (arthral-
gias, purpura, sensory peripheral neuropathy, for in-
stance), a combination of IFNα and ribavirin or
newer antiviral agents should be prescribed and may
suffice to obtain clinical improvement and suppres-
sion of virus replication.14 For patients with severe
symptoms of mixed cryoglobulinemia, PE could be
useful. Although PE are considered a symptomatic
therapy, they are able to cure leg ulcers and to help
reverse other manifestations. However, once started,
PE cannot be discontinued for the majority of pa-
tients. Rituximab, an anti-CD20 monoclonal Ab, could
be an effective treatment when combined with ribavi-
rin and IFNα. Rituximab acts on the B-lymphocyte
clone(s) producing cryoglobulin(s) and, simultane-
ously, the antiviral agent lowers or suppresses virus
replication. This strategy is promising and can obtain
vasculitis regression. At the moment, we have data on
only a few small series of patients15,16 and the results
of prospective controlled trials would be a major con-
tribution in this setting.
HIV-RELATED VASCULITIS
Although rarely observed, HIV has been identified as
the cause of few rare cases of SNV, which mainly af-
fected small-sized vessels. Most patients had skin, pe-
ripheral nerve or central nervous system involve-
ment. Large-, medium- and small-sized arteries can
be affected. The pathogenesis of virus-associated vas-
culitis is heterogeneous, but at least two general
mechanisms have been incriminated: virus replica-
tion might induce direct injury of the vessel wall and
vascular damage might be the result of an immune
mechanism. These mechanisms may be cellular and
or humoral and include deposition of circulating im-
mune complexes andor their in situ formation.
Vasculitis has also been described during diffuse
infiltrative CD8 lymphocytosis syndrome and angio-
centric immunoproliferative lesions.
The therapeutic approach12,17 should be adapted to
the etiological factors: combining antiretroviral drugs
and PE for vasculitis directly caused by HIV infection,
or antiretroviral(s) in combination with another an-
tiviral or antiparasite drug for vasculitis resulting
from other opportunistic agents in HIV-positive pa-
tients. Usually, vasculitides observed during HIV in-
fection are acute and, once remission has been ob-
tained, do not relapse.
TREATMENT ACCORDING TO DISEASE SE-
VERITY
FIRST-LINE THERAPY
It is reasonable to adapt first-line therapy to SNV se-
verity and not systematically prescribe a conventional
regimen. To help the clinician choose the most effec-
tive therapy and to avoid overtreatment, we estab-
lished the five-factor score (FFS),18 which has signifi-
cant prognostic value, and whose parameters, defined
as follows, were responsible for higher mortality: pro-
teinuria >1 gday, renal insufficiency (creatininemia
>140 μmoll), cardiomyopathy, gastrointestinal mani-
festations and central nervous system involvement.
When FFS =0, 5-year mortality was 12%; when FFS
=1, 5-year mortality was 26%; when FFS 2, 5-year
mortality was 46%. Indeed, the results of our study on
278 patients19 with PAN, MPA or CSS demonstrated
that the combination of CYC and corticosteroids was
beneficial for patients with an FFS 2. The patients
who died from severe SNV had more often been
treated with corticosteroids alone than with corti-
costeroids and CYC. Other criteria, like the Birming-
ham vasculitis activity score (BVAS),20 are also used
to determine the intensity of treatment required and
are being tested in the prospective trials proposed by
the European Vasculitis Study (EUVAS) group.
INDICATIONS OF CORTICOSTEROIDS ALONE
Steroids are effective when prescribed alone to treat
PAN and CSS without poor prognosis factors, i.e. FFS
=0, with the results of one of our studies19 demon-
strating that the survival rate was the same as when
patients received a combination of corticosteroids
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and CYC. Based on two recent CHUSPAN trials, we
were able to show that remission could be obtained
with corticosteroids alone and that relapses or pa-
tients whose SNV failed to respond to steroids alone
could benefit from the adjunction of immunosuppres-
sant (CYC or azathioprine).21
INDICATIONS OF CORTICOSTEROIDS AND CY-
CLOPHOSPHAMIDE FOR PAN
PAN prognosis has been transformed by corticoster-
oids and immunosuppressants, especially CYC. Corti-
costeroids alone were able to increase the 5-year sur-
vival rate from 10% for untreated patients to about 55%
in the mid-to-late 1960s.22 Survival was further pro-
longed by adding immunosuppressants, either
azathioprine or CYC to the treatment regimen.
Cyclophosphamide
When CYC is indicated for PAN and CSS patients
with factor(s) of poor prognosis (FFS 1),23 an IV
pulse should be preferred to oral administration. The
IV route may achieve a more rapid clinical response
than oral CYC which is particularly important for pa-
tients with active disease. When combined with corti-
costeroids, IV CYC should not exceed 12 pulses. In a
prospective study on PAN patients with poor-
prognosis factors, we showed that a 6-pulse regimen
not relayed by maintenance therapy was associated
with more relapses than when treatment comprised
12 CYC pulses.23 At present, we recommend pulse
CYC until remission is obtained and then prescribe
maintenance therapy, with azathioprine or
methotrexate for 12 to 18 months, since its efficacy
against ANCA-positive SNV was demonstrated.24
TREATMENT OF ANCA-ASSOCIATED SYS-
TEMIC NECROTIZING VASCULITIDES
ANCA-associated SNV require treatments that are
more substantially codified. However, CSS can be
treated differently from WG and MPA. The recom-
mendations that we have established for PAN treat-
ment can also been applied to CSS and some MPA pa-
tients, with the regimen adapted to disease severity.
TREATMENT OF WEGENER’S GRANULOMATO-
SIS
Corticosteroids and CYC treatments are presently
mandatory for every patient with systemic WG. In
this setting, even though the indication of CYC ad-
ministration is universally accepted, consensus has
not yet been reached concerning which route should
be used. Oral CYC is prescribed at 2 to 3 mgkg
day,11 and the dose can be adapted according to the
therapeutic response, the occurrence of side effects,
renal function andor age. Treatment should be con-
tinued for at least 18 months, but the results of more
recent studies demonstrated that short-term CYC ad-
ministration until remission followed by azathioprine
was as effective as prolonged oral CYC. Shortening
exposure to CYC has a major impact by sharply re-
ducing side effects.
Based on the results of an as yet unpublished trial,
once remission of ANCA-positive WG was obtained
with pulse CYC, it was maintained with azathioprine
or methotrexate, with equivalent outcomes for both
treatment arms. Patients improved equally in both
groups and relapse rates were comparable. The re-
sults of our study also validate methotrexate as a
maintenance therapy but it should not be given as an
induction treatment. However, methotrexate was
evaluated for induction in non-renal WG: although it
was as effective as CYC in the short term, it was less
effective over the long term and relapses occurred
more frequently in the methotrexate arm.25
Among immunosuppressants, mycophenolate
mofetil (MMF) was prescribed for maintenance ther-
apy for 14 WG patients: results were encouraging but
its ability to prevent relapses remains to be proven.26
The EUVAS group is evaluating MMF for mainte-
nance treatment with a regimen comprising pulse or
oral CYC for induction (6 months), then randomized
prescription of azathioprine or MMF to maintain re-
mission (3 years); results of the trial are expected at
the end of 2008.
Pulse CYC, given every 3 to 4 weeks at a dose of
0.5 to 0.7 gm2, was shown to be as good as oral CYC
to induce initial remission,27 but did not maintain it or
limit the high number of relapses after stopping treat-
ment as well as oral CYC. Several other studies have
confirmed our initial results28,29 and recently the
CYCLOPS (daily oral vs pulse CYC during induction
therapy for generalized vasculitis) study, organized
by the EUVAS group, confirmed that pulse and oral
CYC are equally able to achieve remission and that
pulses dramatically lowered the rate of side effects
(unpublished data).
TREATMENT OF MICROSCOPIC POLYANGIITIS
We now recommend treating MPA like WG, based
on the putative common pathogenetic mechanisms
and preliminary results of ongoing trials. However,
we also demonstrated that, when MPA had no poor-
prognosis factors, it could be effectively treated with
corticosteroids alone. Because the majority of MPA
patients have glomerulonephritis, that therapeutic op-
tion can only be prescribed to the fewer than 20%
with only minor symptoms.6
NEW TREATMENTS
In addition to the therapeutic approaches that have
been refined over the past few decades, new drugs
and strategies to treat SNV have been developed and
will, in the near future, dramatically modify the care
of these patients.
Manipulation of the immune system to obtain re-
mission or cure SNV emerged two to three decades
Vasculitis Treatment
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ago with the use of PE and intravenous immuno-
globulins (IVIg) to treat these systemic diseases.
More recently, new drugs targeting cytokines or B
lymphocytes have emerged and deserve evaluation in
patients with disease resistant to conventional regi-
mens or, perhaps also, those with newly diagnosed
SNV.
PLASMA EXCHANGES
PE can be a useful tool, as second-line therapy, in
PAN refractory to conventional regimen(s). Pusey
and coworkers showed that PE can improve renal
function in patients with crescentic glomerulonephri-
tis responsible for severe renal insufficiency (cre-
atininemia >500 μmoll) and enable them to stop di-
alysis.30 A prospective trial organized by the EUVAS
group confirmed that PE were able to improve renal
function significantly but had no effect on survival.31
INTRAVENOUS IMMUNOGLOBULINS
Because of their efficacy, safety and good tolerance,
IVIg alone or as add-on therapy should be considered
for patients with relapsed ANCA-associated SNV and
perhaps to maintain their remissions. In small pro-
spective studies, complete to partial responses, re-
spectively, were observed in 45% to 75% of the pa-
tients given IVIg alone or in combination with other
immunosuppressant(s) andor corticosteroids.32-34
However, in a study on 15 patients,35 only 6 obtained
clinically significant benefits, confined to single-organ
manifestations, without complete disease remission.
Furthermore, the authors showed that the inhibitory
effect of IVIg on anti-proteinase 3 activity was not as-
sociated with clinical improvement. Hence, the opti-
mal role of IVIg in the treatment of ANCA-associated
vasculitis remains to be determined.
One placebo-controlled trial on relapsed ANCA-
associated SNV demonstrated better vasculitis out-
comes for IVIg-treated patients.32 That study evalu-
ated the efficacy, for at least for 2 months, of a single
cycle of IVIg (0.4 gkgday for 5 days) for patients
with persistent disease activity despite conventional
therapy. Seventeen patients were randomized to each
arm to receive a single IVIg cycle or a placebo. After
12 months, responses had been obtained in 14 and 6
patients in the two treatment groups, respectively.
Recently, we conducted a prospective, open, multi-
center trial on French patients with relapsed ANCA-
associated SNV who received a monthly infusion of
IVIg for 6 months in addition to conventional treat-
ment.36 Complete remission was obtained in 13 (59%)
of the 22 patients, without any severe adverse events.
Thus, IVIg might be used in combination with corti-
costeroids and immunosuppressive therapy for pa-
tients experiencing a vasculitis flare under treatment
or shortly after treatment termination.
IVIg are safe and well-tolerated compared with
standard corticosteroids and immunosuppressive
therapy. Although transmission of HCV infection has
been described in the past with this therapy,37 this
possibility has been largely eliminated by the use of
solvent-detergent inactivation of the virus. In addi-
tion, no HBV or HIV transmission has been reported.
Adverse effects occur in 0% to 36% of IVIg recipients
and are usually mild, transient and reversible, consist-
ing most frequently of headaches, low-grade fever,
chills, low-back pain, transient hypotension, nausea
andor intense perspiration; they generally regress
after simply slowing the infusion speed.38
The ability of IVIg to achieve lasting remission of
ANCA-associated SNV was associated with decreased
ANCA titers.39,40 However, that finding was not con-
firmed by others, who reported discrepancies be-
tween the ability of IVIg to neutralize ANCA activity
in vitro and a therapeutic benefit.35
ANTI-TUMOR NECROSIS FACTOR-ALPHA
Anti-TNFα monoclonal Ab (infliximab) or analogues
of its receptor (etanercept) have been proposed to
treat SNV.41 Infliximab, a chimeric anti-TNFα mono-
clonal Ab, in combination with conventional therapy,
led to clinical remission in 88% of the patients with
acute or persistently active ANCA-associated SNV en-
rolled in an open, prospective trial.42 In that study, a
number of infections, including mycobacteria and
some life-threatening, were observed. In 2002, we re-
ported on our experience with infliximab in 10 pa-
tients with severe refractory SNV, including 7 with
WG. All 7 patients obtained complete or partial remis-
sions, with cutaneous eruption being the only ad-
verse effect.41 Ongoing trials on infliximab use in re-
fractory ANCA-associated SNV may lead to its use for
specific subgroups of patients with refractory or re-
lapsed disease.
Etanercept, another TNFα blocker, which is com-
prised of a soluble protein derived from the p75 TNF
receptor fused to the Fc portion of IgG, has been
tested in ANCA-associated SNV, also in conjunction
with conventional therapy, but with a different aim―
to reduce relapse rate. Indeed, compared with pla-
cebo (WGET trial) and in combination with induction
therapy (CYC or methotrexate for limited disease),
etanercept did not confer any advantage for relapse
prevention.43 Etanercept, and perhaps other TNFα
blockers, should probably not be considered for
maintenance therapy but, rather for some refractory
SNV. Moreover, six cases of cancer were diagnosed
during that trial, all in the etanercept arm, and three
more cancers were diagnosed thereafter, two of
which occurred in the placebo group.43
ANTI-CD20 MONOCLONAL ANTIBODIES
Rituximab is a genetically engineered chimeric
murine-human monoclonal IgG1 kappa directed
against the CD20 antigen expressed on the surface of
B lymphocytes. Rituximab seems promising based on
Guillevin L et al.
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the results obtained in the first open trials on patients
with refractory andor relapsed ANCA-associated
WG.44 However, some differences occur in the time
to and extent of the therapeutic responses for consti-
tutional and ‘vasculitic’ manifestations of the disease,
as compared to granulomatous lesions, such as WG
lung nodules or orbital pseudo-tumors, with the latter
regressing more slowly, sometimes only 4 to 6
months after the first rituximab administration.45 Re-
sults of a prospective ongoing North American ran-
domized trial will determine whether rituximab may
also be prescribed as an induction agent, hence re-
placing CYC, and whether it can avoid the need for
another immunosuppressant as maintenance therapy.
At present, and other than the results of the above-
mentioned controlled trials, all these biotherapies
should clearly be restricted to refractory andor re-
lapsed disease. Although the rituximab safety profile
seems good, only long-term results will be able to de-
termine the extent of its applicability. Moreover, the
dose and administration schedules of this biologic,
especially the real need for it, and the exact interval
before reinfusion are not well established.
OTHER BIOTHERAPIES
Anti-thymocyte globulin polyclonal antibody prepara-
tions have also been prescribed and tested in a study
on 15 patients with extremely refractory WG, with
some good primary responses in 13 patients, that was
not sustained in 7 of them.46
Other biological agents are under development and
close to entering phase IIIII trials, for example,
abatacept, a fusion protein (cytotoxic T-lymphocyte
antigen-4 (CTLA4)-Ig) that binds to CD80 and CD86
on antigen-presenting cells, thereby inhibiting opti-
mal T-cell activation by blocking the costimulatory
signal.47 Anti-CD22 monoclonal Ab, another biother-
apy directed against B-lymphocyte proliferation-
inducing soluble factors (BAFF, B-cell-activating fac-
tor of the TNF family, also called BLyS, B-lymphocyte
stimulator),48 andor other forthcoming agents, may
also have a place in the future therapy of ANCA-
associated SNV.
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